Back to top

biotechs: Archive

Sweta Jaiswal, FRM

Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain

Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.

IBB XBI BBH BTEC IDNA GERM

Zacks Equity Research

CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

VRTX CRSP ALNA ETON

Zacks Equity Research

Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

BIIB REGN GILD VRTX BSTC CRSP

Zacks Equity Research

Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?

Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.

ALKS ALXN ALNY AMGN

Zacks Equity Research

Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

SRPT SELB ALNA ETON

Zacks Equity Research

Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales

Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.

BIIB JNJ RHHBY MYL

Zacks Equity Research

Fortress Biotech (FBIO) Enters Oversold Territory

Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

FBIO

Zacks Equity Research

Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

PFE MRK EXEL BMY

Zacks Equity Research

Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M

Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.

ENDP VRTX NVAX BSTC

Zacks Equity Research

Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

RHHBY EBS ABBV APTO

Zacks Equity Research

Aptinyx (APTX) Surges on Promising Stress Disorder Study Data

Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.

JNJ PFE GSK APTX

Swayta Shah

Bet on These 5 Top-Ranked Stocks With Strong Sales Growth

Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.

MMM PKI SWK VRTX AJG

Zacks Equity Research

Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion

Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.

REGN GILD NVS VRTX

Zacks Equity Research

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

MRK GSK BMY VRTX SGEN

Zacks Equity Research

Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC

The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.

AZN RHHBY MRK BMY

Sweta Killa

Weekly ETF Roundup: Broad U.S. Equity Tops, Biotech Flops

ETFs overall gathered about $18.5 billion capital last week, bringing year-to-date inflows of $352.6 billion, ahead of the $211.7 billion seen at this same time a year ago.

JNJ PFE LLY JNK QQQ HYG EFA IWM XBI VTI KRE VXUS FTCS ONLN

Zacks Equity Research

Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis

Regeneron (REGN) gets positive CHMP opinion for Dupixent, recommending extending the approval in the European Union to include children aged 6 to 11 years with severe atopic dermatitis.

REGN SNY EBS CSTL

Zacks Equity Research

Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran

Alnylam (ALNY) gets positive opinion from the CHMP for lumasiran for the treatment of primary hyperoxaluria type 1.

REGN ALNY NVS EBS

Zacks Equity Research

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.

BIIB RHHBY MRK VRTX

Zacks Equity Research

3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

EW RMD QGEN LHCG IDXX

Zacks Equity Research

Eiger (EIGR) Up on Positive Results From Coronavirus Study

Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.

REGN MRK BMY EIGR

Zacks Equity Research

Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study

Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.

AVEO EBS ARMP CSTL

Zacks Equity Research

AnaptysBio (ANAB) Jumps: Stock Rises 7.7%

AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

QGEN ANAB

Nalak Das

5 Stocks With Recent Price Strength to Maximize Your Gains

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

DQ HRI SURF CSTL CVLG

Zacks Equity Research

PDL BioPharma Enters Oversold Territory

PDL BioPharma has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

PDLI